If you’re after big returns, the biotech sector is your go-to destination, although investors should proceed with caution as instead of mighty gains a portfolio can also dwindle alarmingly if a company in the highly volatile sector fails to deliver the goods. Which is what investors evidently felt after taking in the latest news out of Mersana Therapeutics (MRSN) HQ. On Friday, shares shed about 40% of their value after the company provided a clinical trial update. The company disclosed interim data from an expansion cohort in the early-stage study of lead candidate upifitamab rilsodotin (UpRi), earmarked as a treatment for patients with ovarian cancer.
https://www.tipranks.com/news/article/is-mersana-stock-a-buy-right-now-this-is-what-you-need-to-know?utm_source=advfn.com&utm_medium=referral
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Mersana Therapeutics Charts.
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Mersana Therapeutics Charts.